Medscape (6/10, Anderson, Subscription Publication) reports on two studies presented at the American Psychiatric Association’s annual meeting that suggest the use of long-acting injectable antipsychotics “leads to improved adherence and a reduction in suicide attempts for” patients with “severe schizophrenia.” One study included 43 “eligible patients,” while a “second 10-year follow-up study included 344 patients with severe schizophrenia who were treated in mental health units or in a case-managed community-based program.”
Related Links:
— “More Evidence Endorses Benefits of Long-Acting Antipsychotics, “Pauline Anderson, Medscape, June 10, 2019